垂体腺瘤组织学亚型对肢端肥大症缓解与疾病控制的影响
本研究回顾性纳入128例2012至2022年间未接受过药物治疗即行手术的GH或GH-PRL腺瘤患者,评估组织学亚型对术后3个月及末次随访时肢端肥大症缓解和疾病控制的影响。结论认为组织学亚型与肢端肥大症缓解或控制无显著关联,稀疏颗粒型腺瘤虽呈较低缓解率趋势但临床影响有限。
要点
- 组织学亚型与术后3个月及末次随访的肢端肥大症缓解无显著关联。
- 稀疏颗粒型腺瘤缓解率呈较低趋势,但差异未达统计学显著。
- 组织学亚型对末次随访疾病控制率亦无显著影响。
核心结论
- 垂体腺瘤组织学亚型与肢端肥大症术后缓解及疾病控制无显著关联。
- 稀疏颗粒型腺瘤虽呈较低缓解率趋势,但其临床影响似乎有限。
研究设计与样本
- 回顾性单中心研究,纳入128例2012至2022年间未接受 prior 药物治疗即行手术的GH或GH-PRL腺瘤患者。
主要发现
- 腺瘤中61%为纯GH腺瘤(39%致密颗粒型,22%稀疏颗粒型),39%为GH-PRL腺瘤。
临床怎么用
- 组织学亚型不宜单独作为肢端肥大症术后缓解或疾病控制的预测指标。
- 稀疏颗粒型腺瘤可关注其较低缓解率趋势,但当前证据不支持据此改变临床管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Acromegaly results from different histological subtypes of pituitary adenomas, mainly pure GH-secreting adenomas (densely or sparsely granulated) and GH-PRL adenomas. Data on the impact of histological subtype on surgical outcomes in acromegaly remain limited. OBJECTIVES: This study aimed to assess the impact of pituitary adenoma histological subtype on acromegaly remission at 3 months and last follow-up, as well as on disease control. METHODS: We conducted a retrospective, single-center study of 128 patients who underwent surgery for GH or GH-PRL adenomas, without prior medical therapy, between 2012 and 2022. RESULTS: Among the adenomas, 61% were pure GH (39% DG, 22% SG) and 39% were GH-PRL. Compared with DG adenomas, SG adenomas were diagnosed at a younger age (P = .006), were larger (P = .022), expressed more SST5 (P = .032) and less SST2 (P < .001). GH-PRL adenomas were more frequently p53-positive (P = .024), had a higher mitotic count (P = .017) than DG adenomas and expressed more SST2 than SG adenomas (P < .001). The remission rates for DG, GH-PRL and SG adenomas were not significantly different at 3 months (60%, 58% and 43%, P = .337), or at last follow-up (80%, 74% and 57%, P = .091), nor was disease control at last follow-up (94%, 96% and 82%, P = .115) after 42 months. CONCLUSION: Histological subtype was not significantly associated with remission or control of acromegaly. Although a trend toward lower remission rates was observed in SG adenomas, its clinical impact appears limited.
引用
- Monnot A, Ilie MD, Sergeant C, et al. Impact of pituitary adenoma histological subtype on remission and disease control in acromegaly. J Clin Endocrinol Metab. 2026. PMID: 42046892. doi:10.1210/clinem/dgag174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。